Laniquidar

Drugbox
IUPAC_name = 11- [1- [2- [4-(Quinolin-2-ylmethoxy)phenyl] ethyl] piperidin-4-ylidene] -5,6-dihydroimidazo [2,3-b] [3] benzazepine-3-carboxylate

---

width =


width2 =
imagename =
drug_name =
CAS_number = 197509-46-9
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 6450806
DrugBank =
chemical_formula =
C=37 | H=36 | N=4 | O=3
molecular_weight = 584.70 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). [Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. "Best Pract Res Clin Haematol" 2004;12;17(4):641-51. PMID 15494300]

References